


## CALL FOR NEW GROUP LEADERS

### Institut de Recherche en Cancérologie de Montpellier – IRCM

The IRCM is recruiting new group leaders to establish world-class research programs within an interactive and supportive scientific environment. **Applicants demonstrating potential synergies with IRCM’s main research topics will be considered for starting an independent team as soon as January 2027.** Projects at the interface of fundamental and clinical research, particularly those focused on the ICM's flagship pathologies, will be given careful consideration. We welcome **senior team leaders with permanent INSERM / CNRS positions as well as early-career researchers** eligible to ERC, INSERM ATIP-AVENIR and FRM start-up grants.

#### STRATEGY & ENVIRONMENT



# CALL FOR APPLICATION



**MONTPELLIER CANCER CENTER** – is a Comprehensive Cancer Center combining on the same campus a cancer hospital (ICM), a center dedicated to cancer prevention and a cancer research institute (IRCM). It coordinates the INCa-labelled Integrated Cancer Research SIRIC program which promotes integrated multidisciplinary translation research ([www.montpellier-cancer.com](http://www.montpellier-cancer.com)).

The IRCM hosts 19 research teams dedicated to basic and applied cancer research working in close collaboration with clinicians from the ICM and Montpellier/Nîmes University Hospitals (CHU), as well as industrial partners. The IRCM is jointly operated by INSERM, the University of Montpellier and ICM and it functions as an integrated research center with staff from INSERM, CNRS, Montpellier University, ICM and CHU sharing core facilities, administrative and technical support services. IRCM brings together 280 staff members, researchers, clinicians, technicians and students involved in IRCM hosts cutting-edge [core facilities](#) and is an active member of the [UMS Biocampus](#) that provides full access to the 18 technological platforms (proteomics, genomics, mouse facilities, microscopy, etc.) available to the biomedical community.

IRCM is recognized for top level translational research involving clinicians from Montpellier/Nîmes University hospitals and ICM, the regional cancer center of the eastern part of the Occitanie region with an active file of more than 35 000 patients/year. The most frequently pathologies treated at ICM are digestive track, breast, lung, urologic and gynecologic cancers. ICM is also the regional reference center for sarcoma patients. ICM has developed annotated biobanks for these tumors since 2016 to promote translational research related to these pathologies.

## SELECTION OF CANDIDATES

Applicants should provide a CV, a summary of their research project and two recommendation letters sent to [call2024@inserm.fr](mailto:call2024@inserm.fr)

### Calendar

Campaign opening: November, 1<sup>st</sup> 2024

Campaign closure: July, 15<sup>th</sup> 2025

For more info and contact: [call2024.ircm@inserm.fr](mailto:call2024.ircm@inserm.fr)

### Applications Selection:

- Applications submitted before January 1<sup>st</sup> 2025 will be considered for an evaluation by the Scientific Advisory Board in early February 2025 and for INSERM affiliation in the context of the HCERES/INSERM vague A certification.
- Applications received after January 2025 will be evaluated for the creation of emergent teams.